Company profile for EnteroBiotix

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Our vision is to transform the standard of care for patients suffering from substantial unmet clinical needs through microbiome modulating therapeutics and in doing so, create a sustainable pharmaceutical company. It established proprietary MHRA licensed manufacturing capabilities and a supply chain model that enables us to leverage a pipeline of internal and partnered programmes around our lead asset, EBX-101. We operate sit...
Our vision is to transform the standard of care for patients suffering from substantial unmet clinical needs through microbiome modulating therapeutics and in doing so, create a sustainable pharmaceutical company. It established proprietary MHRA licensed manufacturing capabilities and a supply chain model that enables us to leverage a pipeline of internal and partnered programmes around our lead asset, EBX-101. We operate sites in Aberdeen and Glasgow, Scotland.Our Board of Directors are all highly accomplished biopharmaceutical executives that each have a successful track record in delivering value building milestones for shareholders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Unit 2.3 Western Campus Strathclyde Business Park Scotland ML4 3PU
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/05/13/3080024/0/en/EnteroBiotix-Presents-Positive-Data-in-Liver-Cirrhosis-at-EASL-2025.html

GLOBENEWSWIRE
13 May 2025

https://www.globenewswire.com/news-release/2025/05/06/3074896/0/en/EnteroBiotix-Presents-Positive-IBS-C-Data-at-Digestive-Disease-Week-2025.html

GLOBENEWSWIRE
06 May 2025

https://www.globenewswire.com/news-release/2025/05/02/3073044/0/en/EnteroBiotix-to-Present-Results-from-Phase-1b-trial-in-Liver-Cirrhosis-at-EASL-Congress-2025.html

GLOBENEWSWIRE
02 May 2025

https://www.globenewswire.com/news-release/2025/04/28/3069132/0/en/EnteroBiotix-Announces-Oral-Presentation-of-Phase-2a-IBS-C-Results-at-Digestive-Disease-Week-2025.html

GLOBENEWSWIRE
28 Apr 2025

https://www.globenewswire.com//news-release/2025/03/18/3044218/0/en/EnteroBiotix-Announces-Positive-Topline-Phase-2a-Results-with-EBX-102-02-a-Potential-First-in-Class-Treatment-for-Irritable-Bowel-Syndrome-IBS.html

GLOBENEWSWIRE
18 Mar 2025

https://www.globenewswire.com/news-release/2024/11/18/2982739/0/en/EnteroBiotix-Completes-Phase-2-Study-Recruitment-of-EBX-102-02-in-Irritable-Bowel-Syndrome.html

GLOBENEWSWIRE
18 Nov 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty